DPC 963

Drug Profile

DPC 963

Alternative Names: DMP 963

Latest Information Update: 16 Jan 2008

Price : $50

At a glance

  • Originator Bristol-Myers Squibb
  • Class Antiretrovirals; Small molecules
  • Mechanism of Action RNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 16 Nov 2000 A preclinical study in cynomolgus monkeys has been added to the pharmacokinetics section
  • 26 May 2000 A preclinical study has been added to the pharmaockinetics section
  • 22 Mar 1999 A study of the activity of DPC 963 against resistant strains of HIV has been added to the antimicrobial activities section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top